AHCPR Issues Colorectal Cancer Screening Evidence Report

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 3
Volume 6
Issue 3

ROCKVILLE, Md--In the first report issued under its new Evidence-based Practice Initiative, the Agency for Health Care Policy and Research (AHCPR) has reaffirmed that early detection and treatment provide the primary means of preventing death from colorectal cancer.

ROCKVILLE, Md--In the first report issued under its new Evidence-basedPractice Initiative, the Agency for Health Care Policy and Research (AHCPR)has reaffirmed that early detection and treatment provide the primary meansof preventing death from colorectal cancer.

Among the conclusions of the report, based on a review of 3,500 citationsfrom the scientific literature (1966 to 1994):

  • Use of fecal occult blood testing followed by diagnostic evaluationand treatment for positive tests can cut colorectal cancer mortality by15% to 33%.
  • A 60-cm flexible sigmoidoscopy identifies nearly all cancers and polypsgreater than 1 cm in diameter and 75% to 80% of small polyps.
  • Sigmoidoscopy screening can reduce colorectal cancer mortality riskby 59% to 80%.
  • Indirect evidence supports the use of double-contrast barium enemain screening for colorectal cancer.
  • While screening colonoscopy offers the potential to both identify andremove cancers and premalignant lesions, no studies completed to date showan associated mortality reduction.
  • Detecting and removing polyps reduces the incidence of colorectal cancer,and removing early cancers lowers mortality. Although both double-contrastbarium enema and colonoscopy detect polyps and tumors, they have not beenstudied as screening tests.

  • © 1997 by PRR, Inc. All rights reserved.
Related Videos
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.